05289nam 2201369z- 450 991055754520332120231214133613.0(CKB)5400000000044155(oapen)https://directory.doabooks.org/handle/20.500.12854/76606(EXLCZ)99540000000004415520202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierSphingolipidsFrom Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina ObeidBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (292 p.)3-03943-957-X 3-03943-958-8 Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain—which contains the largest amounts of sphingolipids in the body—and first description in 1884 by J.L.W. Thudichum, sphingolipids have been overlooked for almost a century, perhaps due to their complexity and enigmatic nature. When sphingolipidoses were discovered, a series of inherited diseases caused by enzyme mutations involved in sphingolipid degradation returned to the limelight. The essential breakthrough came decades later, in the 1990s, with the discovery that sphingolipids were not just structural elements of cellular membranes but intra- and extracellular signaling molecules. It turned out that their lipid backbones, including ceramide and sphingosine-1-phosphate, had selective physiological functions. Thus, sphingolipids emerged as essential players in several pathologies including cancer, diabetes, neurodegenerative disorders, and autoimmune diseases. The present volume reflects upon the unexpectedly eclectic functions of sphingolipids in health, disease, and therapy. This fascinating lipid class will continue to be the subject of up-and-coming future discoveries, especially with regard to new therapeutic strategies.Sphingolipids Research & information: generalbicsscBiology, life sciencesbicsscS1P receptorinflammationS1P transporterspinster homolog 2barrier dysfunctionanxietydepressionsphingolipidssphingomyelinaseceramidaseSmpd1acid sphingomyelinaseforebraindepressive-like behavioranxiety-like behaviorceramideceramidesceramidasesneurodegenerative diseasesinfectious diseasessphingosine 1-phoshatesphingosine 1-phosphate receptorS1P1-5sphingosine 1-phosphate metabolismsphingosine 1-phosphate antagonistst/inhibitorssphingosine 1-phosphate signalingstrokemultiple sclerosisneurodegenerationfingolimodSphingosine-1-phosphateobesitytype 2 diabetesinsulin resistancepancreatic β cell fatehypothalamussphingosine-1-phosphateischemia/reperfusioncardioprotectionvasoconstrictioncoronary flowmyocardial functionmyocardial infarctalbumintype 1 diabetesbeta-cellsisletsinsulincytokinesS1Panimal modelscystic fibrosisautophagymyriocinAspergillus fumigatusCLN3 diseaseCln3Δex7/8 miceflupirtineallyl carbamate derivativeapoptosiscancergangliosidesimmunotherapymetastasisphenotype switchingsphingosine 1-phosphateSphingosine 1-phosphate (S1P)S1P-lyase (SGPL1)taucalciumhistone acetylationhippocampuscortexastrocytesneuronssphingosine kinaseG-protein-coupled receptorsGαq/11sphingosine kinase 1SK1microRNAtranscription factorhypoxialong non-coding RNAResearch & information: generalBiology, life sciencesvan Echten-Deckert Gerhildedt1307154van Echten-Deckert GerhildothBOOK9910557545203321Sphingolipids3028702UNINA